Wednesday, February 18, 2026 2/18/2026

Tau biomarkers in late-onset psychosis

Award Number: R21MH135148
ORGANIZATION: NATIONAL INSTITUTE OF MENTAL HEALTH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/01/2024
PERIOD OF PERFORMANCE END DATE: 12/31/2026

Group Awards By:

View Award Description

Tau biomarkers in late-onset psychosis - ABSTRACT/PROJECT SUMMARY Psychotic symptoms that occur in advanced age in the absence of an acute medical condition or prominent mood symptoms can represent the late appearance of primary psychotic disorders such as schizophrenia or delusional disorder or can presage the appearance of a neurodegenerative condition such as Alzheimer’s disease (AD). An episode of non-affective psychosis late in life more than doubles the risk of subsequent neurodegenerative disease, with an average time from psychosis to AD diagnosis of 18 months. The biologic mechanisms responsible for the increased risk of dementia in those who experience psychosis are unclear. One hypothesis is reverse causality, in which inchoate neurodegeneration is responsible for psychotic symptoms that emerge in the absence of traditional cognitive hallmarks of dementia. The psychosis then heralds the inception of illness that will eventuate in cognitive decline. An increased burden of tau pathology has been associated with psychosis in AD. In the current pilot study will utilize PI-2620, a novel tau positron emission tomography (PET) ligand, together with single molecule array (SiMOA) peripheral fluid immunoassays to investigate whether there is evidence of elevations in tau biomarkers in a cohort of late-onset psychosis subjects without cognitive impairment. At the completion of this exploratory study, we will know whether there is evidence of tau pathology from high-sensitivity biomarkers in late-onset psychosis that would warrant a larger R01 study that would be focused on longitudinal outcomes assessing the influence of tau biomarker positivity on the risk of conversion to dementia over time.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH	350 COMMUNITY DR	MANHASSET	NY	11030	NASSAU	USA	Mental Health Research Grants	000	2	12/5/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $213,563 )
2025	2025	THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH	350 COMMUNITY DR	MANHASSET	NY	11030	NASSAU	USA	Mental Health Research Grants	000	2	12/20/2024	NON-COMPETING CONTINUATION	$213,563
														Subtotal = $213,563

Issue Date FY: 2024 ( Subtotal = $209,375 )
2024	2024	FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH, THE	350 COMMUNITY DR	MANHASSET	NY	11030	NASSAU	USA	Mental Health Research Grants	000	1	1/30/2024	NEW	$209,375
														Subtotal = $209,375

Grand Total All Awards = $422,938

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Tau biomarkers in late-onset psychosis

Award Number: R21MH135148

ORGANIZATION: NATIONAL INSTITUTE OF MENTAL HEALTH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/01/2024

PERIOD OF PERFORMANCE END DATE: 12/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer